更新于：2023-10-01

Vancomycin Hydrochloride

盐酸万古霉素

更新于：2023-10-01

概要

概要

基本信息

简介Vancomycin是一种小分子药物，作为细胞壁和肽聚糖抑制剂，针对细菌感染。该药物由Eli Lilly & Co.开发，于1954年1月首次获批，适用于多种由敏感菌引起的感染，包括难辨梭菌性腹泻、非并发症皮肤和皮肤结构感染、发热性中性粒细胞减少症和细菌感染和真菌感染等。作为一种强效抗生素，Vancomycin能够破坏细菌细胞壁，从而阻碍有害细菌的生长和传播。然而，长期使用Vancomycin也有潜在的副作用，如肾衰竭、听力损失和耐药性细菌菌株的出现。因此，需要密切监测患者以确保最佳治疗效果，并尽量减少潜在的危害。

药物类型

小分子化药

别名

Ｖardenafil Hydrochloride Hydrate、Vancomycin hydrochloride (JP17/USP)、VCM

+ [24]

靶点

Peptidoglycan(肽聚糖)

作用机制

肽聚糖抑制剂、细胞壁抑制剂

治疗领域

消化系统疾病、遗传病与畸形、呼吸系统疾病+ [7]

在研适应症

艰难梭菌腹泻、简单的皮肤和皮肤结构感染(uSSSI)、粒细胞减少性发热+ [31]

非在研适应症

细菌性结膜炎

原研机构

Eli Lilly & Co.

在研机构

浙江创新生物有限公司

Xellia Pharmaceuticals ApSMylan Laboratories Ltd.

+ [11]

非在研机构

Kurobe Pharmaceuticals, Inc.

最高研发状态(全球)批准上市

首次获批日期(全球)

(1954-01),

革兰氏阳性细菌感染

最高研发状态(中国)批准上市

特殊审评孤儿药 (日本)、快速通道 (美国)、孤儿药 (美国)、优先审评 (美国)

登录后查看首次获批时间轴

结构

分子式C66H76Cl3N9O24

InChIKeyLCTORFDMHNKUSG-XTTLPDOESA-N

CAS号1404-93-9

查看全部结构式(2)

关联

372

项与盐酸万古霉素相关的临床试验

NCT05690048 / Not yet recruiting临床2期IIT

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

The interventional, randomized, placebo-controlled, single blind phase II-trial FLORA will assess safety and immunogenicity of fecal microbiota transfer in combination with standard of care immunotherapy in advanced hepatocellular carcinoma (HCC) in a parallel group design.
Subjects will be randomized 2:1 into either the FMT or placebo group.

开始日期2024-01-01

申办/合作机构

Universitätsklinikum Heidelberg

[+4]

NCT05777603 / Recruiting临床1期IIT

Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Background:
Non-small cell lung cancer (NSCLC) can be hard to treat and is often fatal. People with NSCLC commonly have changes in the bacteria that populate their lungs. These bacterial changes may aid tumor growth. Researchers want to find out if treating the bacteria, too, can help cancer treatment work better.
Objective:
To test 2 inhaled antibiotics (aztreonam and vancomycin), combined with a standard cancer treatment, in people with NSCLC.
Eligibility:
People aged 18 years and older with NSCLC that has returned or progressed after treatment and cannot be treated with surgery.
Design:
Participants will be screened. They will have a physical exam with blood tests. They may blow into a machine to test how well their lungs work. They will have imaging scans. They may need to have a small piece of tissue cut from their tumor (biopsy).
Participants will be treated in six 21-day cycles. They will visit the clinic to receive a drug for cancer treatment on the first day of each cycle. This drug will be administered through a tube attached to a needle inserted into a vein in the arm.
The 2 antibiotic drugs will be in the form of a fine mist that can be inhaled. Participants use a device to take these drugs at home. They will inhale aztreonam up to 3 times a day and vancomycin 1 or 2 times a day. They will take these drugs during only 3 of the treatment cycles.
Biopsies and other tests will be repeated halfway through and after the study treatment.
Follow-up visits will continue for 1 year after study treatment.

开始日期2023-10-04

申办/合作机构

National Cancer Institute

NCT05766670 / Not yet recruiting临床3期IIT

Intramedullary Calcium Sulfate Antibiotic Depot for Prevention of Open Fracture Related Infection: A Randomized Clinical Trial

The goal of this randomized clinical trial is to study the best treatment for open lower leg fractures to prevent infection. The main questions it aims to answer is if treating tibia fracture patients with a calcium sulfate antibiotic depot is better at preventing infection that the standard of care.

开始日期2023-10-01

申办/合作机构

Wake Forest School of Medicine

100 项与盐酸万古霉素相关的专利（医药）

登录后查看更多信息

31,068

项与盐酸万古霉素相关的文献（医药）

2023-12-01·Pharmaceutical biology

Protective effects of vitamin D₃ (cholecalciferol) on vancomycin-induced oxidative nephrotoxic damage in rats.

Article

作者: Rouba Yasser Al-Sroji ; Shaza Al-Laham ; Ahmad Almandili

CONTEXT:

Vancomycin (VCM), an important antibiotic against refractory infections, has been used to treat secondary infections in severe COVID-19 patients. Regrettably, VCM treatment has been associated with nephrotoxicity. Vitamin D₃ can prevent nephrotoxicity through its antioxidant effect.

OBJECTIVE:

This study tests the antioxidant effect of vitamin D₃ in the prevention of VCM-induced nephrotoxicity.

MATERIALS AND METHODS:

Wistar Albino rats (21) were randomly divided into 3 groups: (A) control; (B) VCM 300 mg/kg daily for 1 week; and (C) VCM plus vitamin D₃ 500 IU/kg daily for 2 weeks. All the rats were sacrificed and serum was separated to determine kidney function parameters. Their kidneys were also dissected for histological examination and for oxidative stress markers.

RESULTS:

Lipid peroxidation, creatinine, and urea levels decreased significantly (p < 0.0001) in the vitamin D₃-treated group (14.46, 84.11, 36.17%, respectively) compared to the VCM group that was given VCM (MIC<2 μg/mL) only. A significant increase was observed in superoxide dismutase levels in the vitamin D₃-treated group (p < 0.05) compared to rats without treatment. Furthermore, kidney histopathology of the rats treated with vitamin D₃ showed that dilatation, vacuolization and necrosis tubules decreased significantly (p < 0.05) compared with those in the VCM group. Glomerular injury, hyaline dystrophy, and inflammation improved significantly in the vitamin D₃ group (p < 0.001, p < 0.05, p < 0.05, respectively) compared with the VCM group.

DISCUSSION AND CONCLUSIONS:

Vitamin D₃ can prevent VCM nephrotoxicity. Therefore, the appropriate dose of this vitamin must be determined, especially for those infected with COVID-19 and receiving VCM, to manage their secondary infections.

2023-12-01·Bioactive materials

Hematoma-like dynamic hydrogelation through natural glycopeptide molecular recognition for infected bone fracture repair

Article

作者: Wang, Shenghao ; He, Wenbo ; Wang, Huan ; Liu, Dachuan ; Wang, Miao ; Yang, Huilin ; Pan, Guoqing ; Li, Bin

Infected bone fractures remain a major clinical challenge for orthopedic surgeons. From a tissue regeneration perspective, biomaterial scaffolds with antibacterial and osteoinductive activities are highly desired, while advanced materials capable of mimicking the pathological microenvironment during the healing process of infected tissues remain an area deserving more research. Hematoma, the gel-like blood coagulum, plays an essential role in bone fracture repair because of its ability to serve as a dynamic and temporary scaffold with cytokines for both pathogen elimination and tissue healing. In light of this, we designed a dynamic hydrogel with hematoma-like antimicrobial or reparative performance for infected bone fracture repair in this study. The proposed dynamic hydrogel network was based on the reversible recognition of a natural glycopeptide antibiotic vancomycin (Van) and its target dipeptide D-Ala-D-Ala (AA), which could serve as a hematoma-like scaffold for obliterating bacteria in the fracture region and promoting bone repair by introducing an endogenous osteogenic peptide (OGP). In vivo experiments demonstrated that the hydrogel could rapidly eradicate bacteria, improve bone regeneration and restore the local inflammatory microenvironment. Together, findings from this study imply that the use of hematoma-like dynamic hydrogel could lead to a biomimetic revolution in surgical strategies against susceptible bone fractures.

2023-11-15·Carbohydrate polymers

Thermosensitive injectable dual drug-loaded chitosan-based hybrid hydrogel for treatment of orthopedic implant infections

Article

作者: Akhlaghi, Neda ; Najafpour-Darzi, Ghasem

A myriad of therapeutic agents and drug delivery systems are available to the surgeons for treating orthopedic implant-associated infections (OIAI), but only very few have demonstrated their effectiveness in preventing bacteria colonization and biofilm formation due to challenges in the local and sustainable therapeutic release. To address this issue, in this work, a thermosensitive injectable hydrogel based on chitosan (CH)-integrated hydroxyapatite nanoparticles (HAP NPs) containing vancomycin (Van) and quercetin (QC)-loaded in F127 micelles (CH-HAP-FQ-Van hydrogel) was fabricated with potential application in the treatment of OIAI. This dual drug delivery system demonstrated a pH-sensitive drug release pattern. In addition, 100 % growth inhibition of Staphylococcus aureus for a duration of 14 days was observed. Apart from the strong antioxidant activities owing to the co-administration of QC even after 432 h, this composite hydrogel revealed 95.88 ± 2.8 % S. aureus biofilm eradication. By consideration of degradation stability (53.52 ± 4.24 %) during 60 days along with smart gelation within 10 min at 37 °C and easy injectability, CH-HAP-FQ-Van hydrogel could be used as a promising ideal local drug delivery system for implant-related infections.

230

项与盐酸万古霉素相关的新闻（医药）

2023-09-28

·GlobeNewswire-Health Care

BioNTX Names Osteal Therapeutics 2023 Rising Star

President and CEO, David Thompson, will present at the upcoming iC³ Life Science Summit alongside fellow Rising Star recipients The award follows the announcement by Osteal of an oversubscribed $23M Series C financing round DALLAS, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for orthopedic infections, announced today it has been named a 2023 Rising Star recipient by BioNTX in conjunction with the upcoming iC³ Life Science Summit in Irving, TX. Representing the next-generation of companies dedicated to addressing the greatest challenges in healthcare and life sciences, the Rising Stars are North Texas-based companies with no more than $100 Million in funding or sales, and have been nominated by the life sciences community. Chad Ronholdt, Managing Director of NVB Ventures, and Chair to the BioNTX Tech Transfer Showcase believes, “The Rising Stars program is critical to the future success of life science and healthcare innovation in North Texas because it fosters the ecosystem we live and work in. Investors can see the vibrant company formation and know that the research and development work being done now will become part of the future standards of care across Texas, the Nation, and globally.” Rising Stars will have the opportunity to present their company during the 2023 iC³ Life Science Summit on Thursday, September 28th – Friday, September 29th. “We are honored to be named a 2023 Rising Star recipient by BioNTX,” said David Thompson, President and Chief Executive Officer of Osteal Therapeutics. “Periprosthetic Joint Infection is a devastating condition whose outcomes haven’t improved in a meaningful way in over 20 years. We are dedicated to lifting the burden of this disease on patients, their providers, and the healthcare system. Our success so far is due in no small part to the community we chose to build this company. The friendly business environment and growing life science community fostered by BioNTX in North Texas are key ingredients to our rapid progress.” Osteal recently completed an oversubscribed $23 million Series C equity financing. The proceeds leave Osteal well-funded to submit its New Drug Application to the FDA and accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection (PJI). The company is rapidly approaching completion of enrollment in APEX-2, a multicenter, randomized controlled clinical trial of VT-X7. The VT-X7 clinical program was designed in consultation with the FDA following receipt of orphan drug and qualified infectious disease product designations. About the 2023 iC³ Life Science Summit The 9th Annual BioNTX iC³ Life Science Summit brings together North Texas bioscience and healthcare innovation leaders for a two-day event from Thursday, September 28, 2023 to Friday, September 29, 2023. The iC³ Summit fosters collaboration between thought leaders, knowledge exchange, and explores the latest innovation, products, and services in the life sciences. We invite you to register for the 2023 iC³ Life Science Summit, please click here. About Periprosthetic Joint Infection (PJI) Affecting over 40,000 people in the U.S. annually, PJI is a rare and potentially devastating complication of joint replacement surgery in which pathogenic bacteria colonize the joint prosthesis forming difficult to remove structures called biofilms. Biofilm infections are challenging to resolve, requiring long, invasive, and expensive treatments that are often unsuccessful, resulting in high rates of permanent disability and early death. Recent retrospective analyses demonstrate that the current gold standard for treatment of PJI, two-stage exchange arthroplasty, takes an average of 16 weeks and has a success rate under 50% after 12 months, highlighting the unmet need for faster and more efficacious treatment options. About VT-X7 VT-X7 (vancomycin hydrochloride and tobramycin sulfate for irrigation/VT-X7 irrigation system) is a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin and tobramycin, well-established, broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat PJI. VT-X7 is a seven-day therapy designed to address the unmet clinical need for a rapid, reliable treatment for these challenging infections. In a Phase 2 clinical study of vancomycin and tobramycin delivered by irrigation, 100% of patients were treated and received a new permanent joint prosthesis in seven days, with 93% remaining infection free at one-year. The U.S. Food and Drug Administration granted VT-X7 orphan drug, fast track, and qualified infectious disease product designations. This initial application of VT-X7 represents a first-of-its-kind, multibillion-dollar opportunity to dramatically improve outcomes for a serious unmet medical need. About Osteal Therapeutics, Inc. Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences. The company is leveraging the ability of concentrated, locally delivered antimicrobials to treat the bacterial biofilms typically responsible for musculoskeletal infections while minimizing off-target tissue exposure and associated adverse effects. Osteal employs a low-risk development strategy by using approved drugs with long histories of safety and efficacy as candidates for new routes of local delivery. The company’s lead candidate, VT-X7, is in Phase 2 development to treat periprosthetic joint infections, a serious complication of joint replacement surgery. For more information, please visit: www.ostealtx.com. About BioNTX BioNTX is the premier bioscience and healthcare innovation trade organization in North Texas. We work tirelessly to grow a strong life science community through collaborative peer-to-peer networking events, high-level educational programming, fostering connections to resources, supporting companies with a purchasing consortium, and by being the voice and champion for the North Texas biosciences and healthcare innovation community. Media Contacts: Osteal Therapeutics, Inc.Todd SaundersVice President of MarketingEmail: info@ostealtx.com BioNTXKathleen M. OttoCEOKOtto@BioNTX.org

快速通道孤儿药临床2期合格传染病产品

2023-09-27

·生物谷

Br J Pharmacol: 万古霉素+亚胺培南-西司他丁联合用药对肾脏有保护作用

万古霉素是医院使用的最常见的抗生素之一，但急性肾脏损伤是一个主要的限制因素。据报道，抗生素与万古霉素的常见组合可以加重和改善万古霉素引起的肾脏损伤。万古霉素是医院使用的最常见的抗生素之一，但急性肾脏损伤是一个主要的限制因素。据报道，抗生素与万古霉素的常见组合可以加重和改善万古霉素引起的肾脏损伤。本研究的目的是研究氟氯西林和亚胺培南-西司他丁联合万古霉素对我们的翻译大鼠模型肾损伤的影响。图片来源：https://pubmed.ncbi.nlm.nih.gov/37696768/ 近日，来自美国中西部大学-唐纳斯格罗夫校区的研究者们在Br J Pharmacol杂志上发表了题为“Flucloxacillin worsens while imipenem-cilastatin protects against vancomycin induced kidney injury in a translational rat model”的文章，该研究揭示了万古霉素+亚胺培南-西司他丁联合用药对肾脏有保护作用。研究者用雄性SD大鼠分别给予(1)万古霉素、(2)氟氯西林、(3)万古霉素+氟氯西林、(4)万古霉素+亚胺培南-西司他丁或(5)生理盐水，共4天。万古霉素静脉注射，氟氯西林或亚胺培南-西司他丁腹腔注射。通过药物累积和尿生物标志物，包括尿量、肾损伤分子-1(Kim-1)、聚集素和骨桥蛋白来评估肾脏损伤。探讨万古霉素在肾脏的蓄积与尿肾损伤生物标志物的关系。万古霉素+氟氯西林组的尿量每天都在增加；而在万古霉素组中，仅在第一次服药后尿量增加。万古霉素+氟氯西林组与万古霉素组比较，尿Kim-1/24小时均升高。万古霉素+亚胺培南-西司他丁组与万古霉素组相比，第1、2天尿Kim-1/24小时尿均明显减少。聚集素也有类似的趋势。万古霉素+氟氯西林组较万古霉素+亚胺培南-西司他丁组有更多的万古霉素在肾脏中蓄积。肾组织中万古霉素蓄积与尿Kim-1升高的关系。根据多项肾损伤生物标志物的测定，与万古霉素单独和万古霉素+亚胺培南-西司他丁相比，万古霉素+氟氯西林在翻译大鼠模型中导致了更多的肾脏损伤。万古霉素+亚胺培南-西司他丁联合用药对肾脏有保护作用。不同治疗组和不同给药天数每日尿液生物标记物测量的比较图片来源：https://pubmed.ncbi.nlm.nih.gov/37696768/ 本研究动物模型证实，亚胺培南-西司他丁应该作为一种肾脏保护剂进行研究。然而，尽管西司他丁在临床批准的制剂中可用，如亚胺培南-西司他丁，但抗菌素耐药性的提高将排除常规使用。因此，开发万古霉素-西司他丁制剂是可取的，需要更多关于该组合的益处和风险的信息。（生物谷 Bioon.com）参考文献 Gwendolyn M Pais et al. Flucloxacillin worsens while imipenem-cilastatin protects against vancomycin induced kidney injury in a translational rat model. Br J Pharmacol. 2023 Sep 11. doi: 10.1111/bph.16234.

临床研究

2023-09-21

·BioSpace

Osteal Therapeutics Closes $23M Series C Financing

Financing led by Asteroid Partners with new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corp., HM Capital, Prism Ventures and Medvest Capital. Proceeds will support NDA submission and preparation for commercial launch of lead candidate, VT-X7, a 7-day treatment for periprosthetic join infection. DALLAS, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination therapies for orthopedic infections, announced today the completion of an oversubscribed $23 million Series C equity financing. The proceeds leave Osteal well-funded to submit its New Drug Application (NDA) submission to FDA and accelerate preparation for commercial launch of VT-X7, its lead therapy for the treatment of periprosthetic joint infection (PJI). Asteroid Partners led the round joined by new investor Gideon Strategic Partners and returning investors Johnson and Johnson Development Corporation (JJDC), HM Capital, Prism Ventures and Medvest Capital. In conjunction with the financing, Martin Sands and Steven Sands of Asteroid Partners will join the board as board member and observer respectively. Both will provide valuable insights as Osteal continues to pursue multiple growth paths. The company is rapidly approaching completion of enrollment in APEX-2, a multicenter, randomized controlled clinical trial of VT-X7. APEX-2 is intended to build upon the safety and efficacy evidence obtained from APEX-1, a similarly designed Phase 2 study that successfully met its primary endpoint earlier this year. Both studies were designed in consultation with the FDA following receipt of orphan drug and qualified infectious disease product designations. The company expects to seek NDA approval once APEX-2 reaches its planned endpoints. “This is a very exciting time at Osteal as we expect to achieve a number of critical value-creating milestones in the coming months,” said David Thompson, President and Chief Executive Officer. “This capital raise places Osteal in an excellent position to continue our progress with the VT-X7 program, while also leveraging our technical and scientific expertise to strategically expand our pipeline.” “Today, hip and knee replacements are extremely common. An aging population that is seeking to stay active will drive a roughly three-fold increase in annual procedures between now and 2040. PJIs, while rare, closely track the number of primary and revision joint replacements. The current standard of care for treatment of PJI is associated with significant morbidity, risk of early death and reduced quality of life, driving both the clinical community and regulators to search for better treatment options. Osteal is addressing this significant unmet medical need with a highly novel approach,” said Martin Sands of Asteroid Partners. “I am impressed with the progress this team has made, especially with their clinical program. What I find the most compelling is that when I speak to clinicians, they universally describe the serious unmet need in PJI treatment and quickly understand the potential value of VT-X7. They recognize this solution affords the possibility to both save and change lives,” said Steven Sands, of Asteroid Partners. “I believe Osteal's therapeutic platform will dramatically improve quality of life and outcomes for patients with serious orthopedic infections. I look forward to supporting the team to achieve multiple key milestones over the next 18 months.” About Periprosthetic Joint Infection (PJI) Affecting over 40,000 people in the U.S annually, PJI is a rare and potentially devastating complication of joint replacement surgery in which pathogenic bacteria colonize the joint prosthesis forming difficult to remove structures called biofilms. Biofilm infections are challenging to resolve, requiring long, invasive and expensive treatments that are often unsuccessful, resulting in high rates of permanent disability and early death. Recent retrospective analyses demonstrate that the current gold standard for treatment of PJI, two-stage exchange arthroplasty, takes an average of 16 weeks and has a success rate under 50% after 12 months, highlighting the unmet need for faster and more efficacious treatment options. About VT-X7 VT-X7 (vancomycin hydrochloride and tobramycin sulfate for irrigation/VT-X7 irrigation system) is a novel drug/device combination product designed to deliver therapeutic concentrations of vancomycin and tobramycin, well-established, broad-spectrum antibiotics, directly to the joint space and surrounding tissue to treat PJI. VT-X7 is a seven-day therapy designed to address the unmet clinical need for a rapid, reliable treatment for these challenging infections. In a Phase 2 clinical study of vancomycin and tobramycin delivered by irrigation, 100% of patients were treated and received a new permanent joint prosthesis in seven days with 93% remaining infection free at one year. The US Food and Drug Administration granted VT-X7 orphan drug, fast track, and qualified infectious disease product designations. This initial application of VT-X7 represents a first-of-its-kind, multibillion dollar opportunity to dramatically improve outcomes for a serious unmet medical need. About Osteal Therapeutics, Inc. Osteal Therapeutics is a privately held, clinical-stage biopharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences. The company is leveraging the ability of concentrated, locally delivered antimicrobials to treat the bacterial biofilms typically responsible for musculoskeletal infections while minimizing off-target tissue exposure and associated adverse effects. Osteal employs a low-risk development strategy by using approved drugs with long histories of safety and efficacy as candidates for new routes of local delivery. The company’s lead candidate, VT-X7, is in Phase 2 development to treat periprosthetic joint infections, a serious complication of joint replacement surgery. For more information, please visit: Corporate Contact: Todd Saunders Vice President of Marketing Osteal Therapeutics, Inc. Phone: 469-809-2630 Email: info@ostealtx.com

临床2期快速通道孤儿药合格传染病产品临床结果

外链

KEGG	Wiki	ATC	Drug Bank
D00926	盐酸万古霉素	A07AA09 S01AA28 J01XA01	DB00512

研发状态

适应症	最高研发状态	国家/地区	公司
脓毒症	批准上市	美国更多	浙江创新生物有限公司更多
艰难梭菌腹泻	批准上市	美国更多	浙江创新生物有限公司更多
皮肤和皮肤结构感染	批准上市	美国更多	浙江创新生物有限公司更多
下呼吸道感染	批准上市	美国更多	浙江创新生物有限公司更多
小肠结肠炎	批准上市	美国更多	浙江创新生物有限公司更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02218372 (SUNSHINE, pubmed) AI 标引	临床3期	艰难梭菌感染	148	Fidaxomicin	齋蓋餘顧願簾獵糧壓糧(觸鹹壓觸鑰遞齋繭廠壓) = 窪範築製鏇繭壓製鬱遞觸壓艱鏇蓋鹽鹹鬱憲醖 (襯鬱鹹廠構鹹鬱廠簾選 ) 更多	积极	2019-11-27
				Vancomycin	齋蓋餘顧願簾獵糧壓糧(觸鹹壓觸鑰遞齋繭廠壓) = 獵鹽顧鹹淵築廠齋獵簾觸壓艱鏇蓋鹽鹹鬱憲醖 (襯鬱鹹廠構鹹鬱廠簾選 ) 更多
NCT02057198 (pubmed) AI 标引	临床4期	艰难梭菌感染	33	Fidaxomicin	製夢鏇鏇鹹積鹽膚鬱獵(獵觸廠膚糧艱夢願夢獵) = 壓觸築糧構衊願製夢築淵製齋範艱築廠夢夢壓 (廠簾製鬱選選顧齋鹽憲, 10.7 ~ 15.9) 更多	-	2021-05-21
				Oral Vancomycin	製夢鏇鏇鹹積鹽膚鬱獵(獵觸廠膚糧艱夢願夢獵) = 餘憲願鑰淵醖構顧蓋鹹淵製齋範艱築廠夢夢壓 (廠簾製鬱選選顧齋鹽憲, 4.7 ~ 8.3) 更多
NCT03817125 (MCGRAW, SITC2022) 人工标引	临床1期	转移性黑色素瘤	14	Nivolumab+Vancomycin Hydrochloride+SER 401	(獵衊蓋獵窪壓襯遞齋範) = 願觸鹽構構鏇構構簾鹹簾願鹹鹹廠窪夢構衊選 (範膚憲鏇淵艱選鑰淵選 ) 更多	不佳	2022-11-01
				Nivolumab+placebo	(獵衊蓋獵窪壓襯遞齋範) = 鹹艱醖鏇選鑰繭齋遞壓簾願鹹鹹廠窪夢構衊選 (範膚憲鏇淵艱選鑰淵選 ) 更多
NCT01925066 (pubmed) AI 标引	临床2期	葡萄球菌肺炎 \| 耐甲氧西林金黄色葡萄球菌感染	20	Aerosolised Vancomycin	壓鏇繭齋餘鏇蓋顧餘選(襯鹽簾廠艱鹽醖齋齋選) = 蓋窪願窪艱窪構範選繭淵鑰餘築網襯窪蓋膚廠 (築築鏇簾壓齋積鏇淵餘 ) 更多	-	2020-02-09
NCT02227446 (pubmed) AI 标引	临床3期	骨折	980	Intrawound Vancomycin Powder	選鏇網製夢淵繭餘選鹹(醖簾餘餘獵積鬱鹽獵鏇): risk difference = -3.4 (95% CI, -6.9 ~ 0.1) 更多	-	2021-03-24
				Intrawound Vancomycin Powder
ASAP ECMO study (pubmed) AI 标引	-	危重病	-	vancomycin	衊遞鬱鹹鹹糧襯簾簾繭(鑰醖鬱衊構壓構製簾齋) = 艱廠醖齋網艱遞憲積顧壓艱窪醖淵構繭齋艱顧 (顧製構範鏇願憲鏇獵鬱 )	-	2021-10-11
NCT02790996 (NeoVanc, pubmed) AI 标引	临床2期	感染性休克	242	Optimised regimen of vancomycin	齋範蓋鏇鏇艱築顧鹹夢(獵鹹醖鏇鑰製窪鏇壓壓) = 齋製範網鹹積築鹹夢醖糧餘襯廠鹽鏇夢夢夢壓 (願齋窪艱憲淵範淵壓憲 ) 更多	不佳	2022-01-01
				Standard regimen of vancomycin	齋範蓋鏇鏇艱築顧鹹夢(獵鹹醖鏇鑰製窪鏇壓壓) = 顧鹽觸鹽膚選餘顧鬱蓋糧餘襯廠鹽鏇夢夢夢壓 (願齋窪艱憲淵範淵壓憲 ) 更多
Protocol MK-4261-005 (NCT01597505), Protocol MK-4261-006 (NCT01598311) (pubmed) AI 标引	临床3期	-	1,147	Surotomycin	製獵鑰憲遞壓艱觸繭鏇(構鏇糧鏇範艱膚鹹鑰鑰) = 鏇繭鏇獵鬱膚鹹範簾鬱憲窪鏇範觸艱觸獵醖願 (齋構窪顧鑰鹽構鏇夢餘 )	-	2020-08-03
				Vancomycin	製獵鑰憲遞壓艱觸繭鏇(構鏇糧鏇範艱膚鹹鑰鑰) = 夢獵窪網網鹹夢齋夢襯憲窪鏇範觸艱觸獵醖願 (齋構窪顧鑰鹽構鏇夢餘 )
NCT03685747 (pubmed) AI 标引	临床1期	-	4	vancomycin	廠繭鏇齋顧夢簾淵範鹹(構網醖憲鑰糧觸簾衊願) = 鑰簾鏇鹹繭繭壓衊鑰淵糧簾鏇製膚蓋蓋艱衊積 (遞淵鬱獵獵膚範糧艱齋 ) 更多	-	2021-11-09
IMPACT 1 and IMPACT 2 (pubmed) AI 标引	临床3期	艰难梭菌感染	1,263	Cadazolid 250 mg	窪顧願壓窪壓糧簾繭範(憲觸簾築醖襯艱範蓋糧) = 願範壓獵廠齋糧蓋廠鬱醖獵願糧襯觸壓醖鏇襯 (夢鑰遞餘鏇範餘鑰構窪 )	不佳	2019-03-01
				Vancomycin 125 mg	窪顧願壓窪壓糧簾繭範(憲觸簾築醖襯艱範蓋糧) = 壓遞遞選獵蓋齋艱選醖醖獵願糧襯觸壓醖鏇襯 (夢鑰遞餘鏇範餘鑰構窪 )